We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Mixed Chimeric Transplantation for Primary Amyloidosis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00186095
Recruitment Status : Withdrawn (Closed, never started.)
First Posted : September 16, 2005
Last Update Posted : October 10, 2007
Information provided by:
Stanford University

Brief Summary:
To evaluate the role of nonmyeloablative allogeneic transplantation in Amyloidosis.

Condition or disease Intervention/treatment
Amyloidosis Procedure: autologous followed by nonmyeloablative allogeneic transplant

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 45 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Mixed Chimeric Transplantation for Primary Amyloidosis
Study Start Date : December 2000
Estimated Study Completion Date : September 2006

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Amyloidosis
U.S. FDA Resources

Primary Outcome Measures :
  1. Treatment of patients with nonmyeloablative allogeneic transplant for amyloidosis.

Secondary Outcome Measures :
  1. Toxicity of therapy
  2. Changes in marrow and serum abnormalities
  3. Improvement in end-organ function.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   up to 60 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • primary amyloidosis
  • adequate organ function
  • matched sibling donor

Exclusion Criteria:

  • evidence of multiple myeloma
  • HIV positive

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00186095

Sponsors and Collaborators
Stanford University
Principal Investigator: Keith Stockerl-Goldstein, MD Stanford University

ClinicalTrials.gov Identifier: NCT00186095     History of Changes
Other Study ID Numbers: BMT129
First Posted: September 16, 2005    Key Record Dates
Last Update Posted: October 10, 2007
Last Verified: October 2007

Keywords provided by Stanford University:
cell transplantation

Additional relevant MeSH terms:
Proteostasis Deficiencies
Metabolic Diseases